10-Q: BioScience Health Innovations Reports Q2 2026 Results, Revenue Declines

BioScience Health Innovations Inc. reported a net loss of $185,753 for the three months ended June 30, 2026, with revenues falling to $1,036,364 from $1,757,463 in the prior year period.

Summary

• BioScience Health Innovations Inc. reported a net loss of $185,753 for the three months ended June 30, 2026, a significant shift from a net income of $457,704 in the same period last year.
• Revenue for the quarter decreased to $1,036,364 from $1,757,463 in Q2 2025, attributed to sales channel adjustments, increased competition, and a rescheduled major customer order.
• Operating expenses increased to $877,365 from $616,774, driven by efforts to uplist to a senior exchange, increased marketing, R&D, and accounting system upgrades.
• For the six months ended June 30, 2026, the company reported a net loss of $415,660, compared to a net income of $884,502 in the prior year, with revenues declining to $1,787,310 from $2,984,533.
• The company's cash balance was $712,378 as of June 30, 2026, and management believes this is sufficient to meet obligations over the next year.
• Significant investments were made in operational infrastructure, including supply chain solidification, vendor qualification, and an upgrade to the NetSuite ERP system.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to a significant revenue decline and net loss in the current period, despite management's optimistic outlook and strategic repositioning.

Positives

• Management believes its current cash balance of $712,378 is sufficient to meet obligations over the next year.
• The company has solidified its supply chain, qualified ingredient vendors, and upgraded its accounting and ERP infrastructure to NetSuite.
• Progress is being made towards uplisting to a major exchange, with advisors engaged and a Regulation A round completed.
• The company is developing a patent-pending delivery system called Mods Max, which is seen as a core value driver and defensible moat.
• Strategic focus on large, growing markets such as testosterone support, NAD/cellular wellness, GLP-1 support, menopause, peptides, and clean skincare.
• Development of patent-pending products related to Methylene Blue and mitochondrial health.

Negatives

• Net loss of $185,753 for the three months ended June 30, 2026, compared to a net income of $457,704 in the prior year.
• Revenue for the three months ended June 30, 2026, decreased to $1,036,364 from $1,757,463 in the prior year.
• Net loss of $415,660 for the six months ended June 30, 2026, compared to a net income of $884,502 in the prior year.
• Revenue for the six months ended June 30, 2026, decreased to $1,787,310 from $2,984,533 in the prior year.
• Operating expenses increased significantly in both the three-month and six-month periods.
• Disclosure controls and procedures were found to be ineffective as of June 30, 2026, with material weaknesses identified in internal accounting resources, segregation of duties, board independence, and documentation.
• The company has an accumulated deficit of $114,653 as of June 30, 2026.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate future revenues and obtain necessary financing.
• Increased competition and evolving customer needs are impacting sales channels and marketing approaches.
• A significant order from a major co-brand customer was rescheduled due to unforeseen events.
• The company is seeking to uplist to a senior exchange, which involves regulatory and market conditions that are not assured.
• Material weaknesses in internal control over financial reporting have been identified, including a lack of sufficient internal accounting resources, segregation of duties, an independent board, and written policies.
• The company's patent applications are still pending, and there is no guarantee they will be granted or provide the expected commercial benefits.

Future Outlook

Management is confident that the operational and infrastructure improvements completed in the first half of 2026, combined with new product launches, expanding distribution, and capital markets progress, will lead to revenue growth and improved product margins by year-end. The company is also progressing towards uplisting to a major exchange.

Management Comments

• "As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings."
• "The first half of 2026 has been deliberately structured as a preparation-for-scale phase. We solidified our supply chain, qualified ingredient vendors, trained internal staff, maintained an active R&D pipeline, separated from the related party that built our initial supply chain, upgraded our accounting and ERP infrastructure to NetSuite, closed our initial Regulation A round (crossing the shareholder threshold needed for a senior-exchange uplist), amended that offering, and engaged specialized advisors to guide our exchange application."
• "Management is confident that by year-end we will demonstrate both revenue growth and bottom-line (product-margin) growth as these investments convert into scalable sales."
• "The relevant question is whether the Company exits this period with a stronger, more scalable, higher-margin, and better-governed system and management believes it does."

Industry Context

StockSavvy.ai notes that BioScience Health Innovations is operating in highly competitive and rapidly evolving markets, including mental health, wellness, and specialized supplements. The company's strategy hinges on its proprietary 'Mods Max' delivery system, aiming to differentiate itself through enhanced absorption and novel delivery methods in categories with significant growth potential, such as NAD, GLP-1 support, and peptide therapeutics.

Comparison to Industry Standards

• The company's revenue decline in the first half of 2026 contrasts with the growth observed in many segments of the health and wellness market, such as the NAD market projected at a 15% CAGR and the GLP-1 drug market at an 18% CAGR.
• While the company aims to compete in the testosterone replacement therapy (TRT) market, estimated at $2.1-2.9 billion, its approach focuses on a non-injection alternative, differentiating from traditional pharmaceutical offerings.
• The company's strategy to enter the peptide therapeutics market, estimated at $49-54 billion, is based on offering oral and nasal delivery, a significant innovation compared to the industry's historical reliance on injections.
• In the clean skincare market, estimated between $9 billion and $48 billion, the company is leveraging its Mods Max system for enhanced absorption and antioxidant benefits, aiming to capture market share from competitors.

Corporate Governance

Legal Proceedings

• Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving the company or its properties.
• No director, officer, or affiliate is a party adverse to the company in any legal proceeding or has an adverse interest.

Related Party Transactions

• During the six months ended June 30, 2026, the company purchased $745,060 worth of inventory from Ageless Holdings, LLC (an entity owned by management/board members), received $3,060 in advances, and repaid $150,000 of advances.
• A promissory note for $460,402 was entered into on March 28, 2026, with Ageless Holdings, LLC, carrying a 7% interest rate and maturing December 31, 2026.
• During the six months ended June 30, 2025, the company purchased $1,153,197 of inventory from Ageless Holdings, LLC, paid $25,000 for services, received $1,391,635 in advances, and repaid $1,322,000 of advances.

Stakeholder Impact

• Shareholders may be concerned by the decline in revenue and the net loss reported for the period, despite management's positive outlook.
• The identified material weaknesses in internal controls could impact investor confidence and the company's ability to meet reporting requirements.
• The planned uplisting to a senior exchange could potentially increase investor access and liquidity for shareholders.
• Suppliers may be impacted by the company's efforts to solidify its supply chain and qualify new vendors.
• Creditors may be affected by the company's liquidity position and ongoing capital raise efforts.

Next Steps

• Continue to focus on gaining traction for mental health and general wellness products.
• Maximize value for stakeholders through partnerships and strategic alliances.
• Complete the amended Regulation A offering and make application to a senior exchange.
• Appoint initial independent board members in connection with the uplisting.
• Expand product footprint and sales on Amazon.
• Launch new product categories across testosterone support, GLP-1 support, menopause, peptides, and clean skincare.
• Implement cybersecurity processes, technologies, and controls.
• Establish written policies and procedures for internal control of financial reporting and hire additional accounting personnel.

Key Dates

Recommendation

The company shows promising innovation with its Mods Max delivery system and targets large, growing markets. However, the significant revenue decline, net loss, and identified material weaknesses in internal controls present considerable risks. While management is optimistic and pursuing a capital raise and exchange uplist, the current financial performance and control deficiencies warrant a cautious 'hold' stance until clearer signs of sustained revenue growth and improved financial reporting accuracy emerge.

Keywords

BioScience Health Innovations, Methylene Blue, Mitochondrial Health, Mods Max Delivery System, Wellness Products, Nutritional Supplements, Health Innovations, Form 10-Q